Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

6.3%

5 terminated/withdrawn out of 79 trials

Success Rate

91.5%

+5.0% vs industry average

Late-Stage Pipeline

39%

31 trials in Phase 3/4

Results Transparency

6%

3 of 54 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 3
26(34.2%)
Phase 1
23(30.3%)
Phase 2
18(23.7%)
Phase 4
5(6.6%)
N/A
4(5.3%)
76Total
Phase 3(26)
Phase 1(23)
Phase 2(18)
Phase 4(5)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (79)

Showing 20 of 79 trials
NCT01148849Phase 1Completed

Safety Study of MGAH22 in HER2-positive Carcinomas

Role: collaborator

NCT03920540Phase 3Completed

A Study of GC1111 in Hunter Syndrom Patients

Role: lead

NCT05422508Phase 2Recruiting

Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

Role: lead

NCT01624532Phase 2Completed

A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109

Role: lead

NCT02783482Phase 3Completed

Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

Role: lead

NCT03947138Phase 3Completed

A Study of GC3107(BCG Vaccine) in Healthy Infants

Role: lead

NCT03454620Phase 1Completed

A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy

Role: lead

NCT03855696Phase 1Completed

A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients

Role: lead

NCT04555148Phase 2Completed

COVIDIG (COVID-19 Hyper-ImmunoGlobulin)

Role: lead

NCT03375502Phase 2Completed

A Study of MG1111 in Healthy Children

Role: lead

NCT03820414Phase 1Completed

Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

Role: collaborator

NCT04611724Phase 2Unknown

A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer

Role: collaborator

NCT03492710Phase 3Withdrawn

Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency

Role: lead

NCT04175522Phase 2Completed

Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:

Role: lead

NCT04003844Phase 4Completed

Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease

Role: lead

NCT03519113Phase 2Unknown

HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102

Role: lead

NCT04238975Phase 2Unknown

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults

Role: lead

NCT03801798Phase 2Unknown

A Study of GC1102(Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients

Role: lead

NCT03590808Not ApplicableCompleted

Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor

Role: collaborator

NCT02159976Not ApplicableCompleted

Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea

Role: collaborator